W Molecular Test to Improve Prostate Cancer DiagnosisPROGENSA PCA3 to help world’s first molecular urine test for the diagnosis of prostate cancer, was life life. Scientific data shows that the test clinical clinical tool. 1-4 PROGENSA PCA3 and distributed by and distributed by Gen-Probe Incorporated. Chris Hiley, Head of Policy and Research Management, The Prostate Cancer Charity said. Prostate cancer can be difficult to diagnose Current diagnostic tools for prostate cancer, such as serum PSA test, have their disadvantages as PROGENSA TM PCA3 is a welcome addition .. Re – invigorating the role of the psychiatrist as part of a team in which role assignments are clearly could lead to better results.Fava GA, Park SK, Dubovsky S. The psychiatric hospital: a new model. World Psychiatry. 2008 Oct, 7 :177-81.
Gros head J, Aubin SM, PCA3 molecular urine test DerasILet al.APTIMA: help develop a method for diagnosing prostate cancer. Clin Chem 2006, 52 :1089 – 1095th R. 18rby PCA3 improves diagnosis of prostate cancer KIRBY2007. Practitioner 2007, 251 : 18, Marks LS, Fradet Y, DerasILet undergo al.PCA3 molecular urine test for prostate cancer in men repeat biopsy. Urology 2007, 69 :532-535. Schalken J. Interview with Jack Schalken. PCA3 and its use as a diagnostic test for prostate cancer. Interview by Christine McKillop. EUR Urol 2006, 50 :153-154. The Prostate Cancer Charity. The PSA test. (more…)